STARD8

Across TCGA pan-cancer cohorts, STARD8 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STARD8 data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher STARD8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STARD8 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

READ, UCEC, and SARC are the cancer types where STARD8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	All	0.111	0.909	<.001	30	view →
UCEC	OS	Median	II,III,IV	0.888	0.454	.026	10	view →
SARC	DFS	Median	All	0.161	0.543	.021	6	view →
SCLC	DFS	Median	All	1.000	0.212	.018	5	view →
SKCM	OS	Median	All	0.463	0.786	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STARD8–READ (OS)

Open the READ breakdown →